Editor: Aigerim Akhmetova
Author: Tursunova Balkadisha
Translator: Tursunova Balkadisha
This article was written by Canadian scientists from the Snyder Institute of chronic diseases and the Alberta children's hospital Research Institute, Cumming school of Medicine, University of calgary, Alberta. The researchers studied the chemical composition of substances from vanilloid compounds and their mechanism of action. The receptor potential-TRPV1 consists of a non-specific cation channel that is sensitive to harsh vanilloid compounds (for example, capsaicin). It is sensitive to harmful stimuli (heat, low pH, or inflammatory mediators).
Pharmacological and genetic studies have confirmed that TRPV1 is a therapeutic target in several preclinical models of chronic pain, including cancer, neuropathic, postoperative, and musculoskeletal pain. When studying capsaicin, it was found that it causes long-term blocking of nociceptors and, thus, we can say that a new class of therapeutic agents with a long-term analgesic effect is being opened. The list of TRPV1 agonists undergoing clinical trials for the treatment of chronic pain was also reviewed, and new indications, formulations, or combined treatments with capsaicin were discussed.
While analgesia with standard medications for patients with chronic pain is outdated, the latest drugs targeting TRPV1 can quickly establish themselves as analgesics for a wide range of pain conditions.
Source: https://pubmed.ncbi.nlm.nih.gov/33165872/
